Partnervest Advisory Services LLC acquired a new stake in Biogen Inc (NASDAQ:BIIB) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 914 shares of the biotechnology company’s stock, valued at approximately $213,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Comerica Securities Inc. increased its holdings in shares of Biogen by 18.9% during the fourth quarter. Comerica Securities Inc. now owns 2,207 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 351 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Biogen by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 2,713,577 shares of the biotechnology company’s stock valued at $815,190,000 after acquiring an additional 144,464 shares in the last quarter. CWM LLC increased its holdings in shares of Biogen by 52.2% during the first quarter. CWM LLC now owns 420 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 144 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Biogen during the first quarter valued at about $846,000. Finally, Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Biogen by 38.5% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 71,318 shares of the biotechnology company’s stock valued at $16,858,000 after acquiring an additional 19,834 shares in the last quarter. Hedge funds and other institutional investors own 90.77% of the company’s stock.
NASDAQ BIIB traded down $3.62 during trading hours on Tuesday, reaching $220.14. The stock had a trading volume of 42,148 shares, compared to its average volume of 1,164,077. The stock has a fifty day moving average of $234.00 and a 200 day moving average of $251.07. The stock has a market cap of $41.66 billion, a P/E ratio of 8.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.99. Biogen Inc has a 52-week low of $216.12 and a 52-week high of $358.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.22 and a current ratio of 2.46.
Several equities analysts have recently issued reports on BIIB shares. Oppenheimer set a $290.00 price objective on shares of Biogen and gave the company a “buy” rating in a report on Sunday, May 5th. Cowen restated a “buy” rating and set a $275.00 price objective on shares of Biogen in a report on Tuesday, July 30th. Standpoint Research upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Wednesday, June 5th. Piper Jaffray Companies restated a “hold” rating on shares of Biogen in a report on Friday, July 26th. Finally, Credit Suisse Group started coverage on shares of Biogen in a report on Monday, May 20th. They set an “underperform” rating and a $198.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, twenty-three have given a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $269.74.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.